Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity

Roxburgh, R. H. S. R., Seaman, S. R., Masterman, T., Hensiek, A. E., Sawcer, S. J., Vukusic, S., Achiti, I., Confavreux, C., Coustans, M., le Page, E., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000156155.19270.f8 · Cited by 963 · see citing works

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845 · see citing works

Control of local protein synthesis and initial events in myelination by action potentials

Wake, H., Lee, P. R., & Fields, R. D. (2011) · Science · doi:10.1126/science.1206998 · Cited by 636 · see citing works

Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo

Cirrito, J. R., Kang, J.-E., Lee, J., Stewart, F. R., Verges, D. K., Silverio, L. M., Bu, G., Mennerick, S., & Holtzman, D. M. (2008) · Neuron · doi:10.1016/j.neuron.2008.02.003 · Cited by 635 · see citing works

Bace1 modulates myelination in the central and peripheral nervous system

Hu, X., Hicks, C. W., He, W., Wong, P., Macklin, W. B., Trapp, B. D., & Yan, R. (2006) · Nature Neuroscience · doi:10.1038/nn1797 · Cited by 608 · see citing works

Simultaneous Measurement of β-Amyloid(1–42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology

Olsson, A., Vanderstichele, H., Andreasen, N., Meyer, G. D., Wallin, A., Holmberg, B., Rosengren, L., Vanmechelen, E., & Blennow, K. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.039347 · Cited by 424 · see citing works

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

Gunnarsson, M., Malmeström, C., Axelsson, M., Sundström, P., Dahle, C., Vrethem, M., Olsson, T. P., Piehl, F., Norgren, N., Rosengren, L., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22247 · Cited by 346 · see citing works

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS

Malmeström, C., Haghighi, S., Rosengren, L., Andersen, O., & Lycke, J. (2003) · Neurology · doi:10.1212/01.wnl.0000098880.19793.b6 · Cited by 318 · see citing works

Determination of β-Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry

Portelius, E., Westman-Brinkmalm, A., Zetterberg, H., & Blennow, K. (2006) · Journal of Proteome Research · doi:10.1021/pr050475v · Cited by 206 · see citing works

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

Axelsson, M., Malmeström, C., Nilsson, S., Haghighi, S., Rosengren, L., & Lycke, J. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5863-2 · Cited by 190 · see citing works

A novel pathway for amyloid precursor protein processing

Portelius, E., Price, E. A., Brinkmalm, G., Stiteler, M., Olsson, M., Persson, R., Brinkmalm, A., Zetterberg, H., Simon, A. J., & Blennow, K. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.06.002 · Cited by 169 · see citing works

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection

Gisslén, M., Krut, J. J., Andréasson, U., Blennow, K., Cinque, P. M., Brew, B. J., Spudich, S., Hagberg, L., Rosengren, L., Price, R. W., et al. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-63 · Cited by 147 · see citing works

Characterization of Amyloid β Peptides in Cerebrospinal Fluid by an Automated Immunoprecipitation Procedure Followed by Mass Spectrometry

Portelius, E., Tran, A. J., Andréasson, U., Persson, R., Brinkmalm, G., Zetterberg, H., Blennow, K., & Brinkmalm, A. (2007) · Journal of Proteome Research · doi:10.1021/pr0703627 · Cited by 146 · see citing works

Multiple sclerosis and Alzheimer's disease

Dal Bianco, A., Bradl, M., Frischer, J., Kutzelnigg, A., Jellinger, K., & Lassmann, H. (2008) · Annals of Neurology · doi:10.1002/ana.21240 · Cited by 123 · see citing works

Cognitive and Cortical Plasticity Deficits Correlate with Altered Amyloid-β CSF Levels in Multiple Sclerosis

Mori, F., Rossi, S., Sancesario, G. M., Codecà, C., Mataluni, G., Monteleone, F., Buttari, F., Kusayanagi, H., Castelli, M., Motta, C., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.187 · Cited by 98 · see citing works

Amyloid precursor protein (APP) expression in multiple sclerosis lesions

Gehrmann, J., Banati, R. B., Cuzner, M. L., Kreutzberg, G. W., & Newcombe, J. (1995) · Glia · doi:10.1002/glia.440150206 · Cited by 96 · see citing works

An online nano‐LC‐ESI‐FTICR‐MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid

Brinkmalm, G., Portelius, E., Öhrfelt, A., Mattsson, N., Persson, R., Gustavsson, M. K., Vite, C. H., Gobom, J., Månsson, J., Nilsson, J., et al. (2012) · Journal of Mass Spectrometry · doi:10.1002/jms.2987 · Cited by 92 · see citing works

Multiple sclerosis diagnostic criteria: three years later

Polman, C. H., Wolinsky, J. S., & Reingold, S. C. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1135oa · Cited by 88 · see citing works

Orthogonal projections to latent structures as a strategy for microarray data normalization

Bylesjö, M., Eriksson, D., Sjödin, A., Jansson, S., Möritz, T., & Trygg, J. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-207 · Cited by 84 · see citing works

γ-Secretase-dependent amyloid-β is increased in Niemann-Pick type C

Mattsson, N., Zetterberg, H., Bianconi, S. E., Yanjanin, N. M., Fu, R., Månsson, J., Porter, F. D., & Blennow, K. (2010) · Neurology · doi:10.1212/wnl.0b013e318208f4ab · Cited by 78 · see citing works

Aspects of β-Amyloid as a Biomarker for Alzheimer's Disease

Andréasson, U., Portelius, E., Andersson, M. E., Blennow, K., & Zetterberg, H. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.1.59 · Cited by 74 · see citing works

Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease

Rosén, C., Andréasson, U., Mattsson, N., Marcusson, J. O., Minthon, L., Andreasen, N., Blennow, K., & Zetterberg, H. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8171-4 · Cited by 72 · see citing works

Low cerebrospinal fluid β-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment

Sjögren, M. J. C., Gisslén, M., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02285-6 · Cited by 71 · see citing works

Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis

Rossi, S., Mancino, R., Bergami, A., Mori, F., Castelli, M., Chiara, V. D., Studer, V., Mataluni, G., Sancesario, G. M., Parisi, V., et al. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511410342 · Cited by 66 · see citing works

Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism

Mattsson, N., Bremell, D., Anckarsäter, R., Blennow, K., Anckarsäter, H. S., Zetterberg, H., & Hagberg, L. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-51 · Cited by 64 · see citing works

Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis

Mattsson, N., Axelsson, M., Haghighi, S., Malmeström, C., Wu, G., Anckarsäter, R., Sankaranarayanan, S., Andreasson, U., Fredrikson, S., Gundersen, A., et al. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458508100031 · Cited by 61 · see citing works

Cortical lesions and cognitive impairment in multiple sclerosis

Rinaldi, F., Calabrese, M., Grossi, P., Puthenparampil, M., Perini, P., & Gallo, P. (2010) · Neurological Sciences · doi:10.1007/s10072-010-0368-4 · Cited by 56 · see citing works

Decreased levels of soluble amyloid β-protein precursor and β-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus

Trysberg, E., Höglund, K., Svenungsson, E., Blennow, K., & Tarkowski, A. (2004) · Arthritis Research & Therapy · doi:10.1186/ar1040 · Cited by 29 · see citing works

Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain

Mattsson, N., Johansson, P., Hansson, O., Wallin, A., Johansson, J.-O., Andréasson, U., Andersen, O., Haghighi, S., Olsson, M., Stridsberg, M., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091651 · Cited by 20 · see citing works

Cerebrospinal Fluid Levels of Soluble Amyloid Precursor Protein and β-Amyloid 42 in Patients with Multiple Sclerosis, Neuromyelitis Optica and Clinically Isolated Syndrome

Mai, W.-H., Hu, X.-Q., Lu, Z.-H., Peng, F.-H., & Wang, Y.-G. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900641 · Cited by 17 · see citing works

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

Palmqvist, S., Schöll, M., Strandberg, O., Mattsson, N., Stomrud, E., Zetterberg, H., Blennow, K., Landau, S., Jagust, W., & Hansson, O. (2017) · Nature Communications · doi:10.1038/s41467-017-01150-x · Cited by 911 · see citing works

Amyloid biomarkers in Alzheimer's disease

Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · see citing works

Immunology of relapse and remission in multiple sclerosis.

Steinman, L. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120227 · Cited by 307 · see citing works

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

Mattsson, N., Insel, P. S., Donohue, M., Landau, S., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Weiner, M. W. (2015) · Brain · doi:10.1093/brain/awu367 · Cited by 237 · see citing works

Amyloid-beta and tau protein beyond Alzheimer’s disease

Abyadeh, M., Gupta, V., Paulo, J. A., Mahmoudabad, A. G., Shadfar, S., Mirshahvaladi, S., Gupta, V. B., Nguyen, C. T. O., Finkelstein, D. I., You, Y., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.386406 · Cited by 121 · see citing works

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

Mattsson, N., Insel, P. S., Landau, S. M., Jagust, W., Donohue, M., Shaw, L. M. J., Trojanowski, J. Q., Zetterberg, H., Blennow, K., Weiner, M. W., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.81 · Cited by 106 · see citing works

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 97 · see citing works

Neural Plasticity in Multiple Sclerosis: The Functional and Molecular Background

Ksiazek-Winiarek, D. J., Szpakowski, P., & Glabinski, A. R. (2015) · Neural Plasticity · doi:10.1155/2015/307175 · Cited by 83 · see citing works

CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes

Constantinides, V. C., Paraskevas, G. P., Emmanouilidou, E., Petropoulou, O., Bougea, A. M., Vekrellis, K., Evdokimidis, I., Stamboulis, E., & Kapaki, E. N. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.09.039 · Cited by 80 · see citing works

CSF Aβ1‐42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease

Lista, S., Garaci, F., Ewers, M., Teipel, S. J., Zetterberg, H., Blennow, K., & Hampel, H. J. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.506 · Cited by 76 · see citing works

CD8+ T Cell-Mediated Mechanisms Contribute to the Progression of Neurocognitive Impairment in Both Multiple Sclerosis and Alzheimer's Disease?

Stojić-Vukanić, Z., Hadžibegović, S., Nicole, O., Nacka-Aleksić, M., Leštarević, S., & Leposavić, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.566225 · Cited by 61 · see citing works

Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature

Zetterberg, H. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12618 · Cited by 57 · see citing works

The secreted APP ectodomain sAPPα, but not sAPPβ, protects neurons against Aβ oligomer-induced dendritic spine loss and increased tau phosphorylation

Tackenberg, C., & Nitsch, R. M. (2019) · Molecular Brain · doi:10.1186/s13041-019-0447-2 · Cited by 56 · see citing works

Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging

Matías‐Guiu, J. A., Oreja‐Guevara, C., Cabrera‐Martín, M. N., Moreno‐Ramos, T., Carreras, J. L., & Matías‐Guiu, J. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00053 · Cited by 54 · see citing works

Astroglial activation and altered amyloid metabolism in human repetitive concussion

Shahim, P., Tegner, Y., Marklund, N., Höglund, K., Portelius, E., Brody, D. L., Blennow, K., & Zetterberg, H. (2017) · Neurology · doi:10.1212/wnl.0000000000003816 · Cited by 49 · see citing works

Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings

Blennow, K., & Zetterberg, H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.006 · Cited by 46 · see citing works

CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis

Pietroboni, A., di Cola, F. S., Scarioni, M., Fenoglio, C., Spanó, B., Arighi, A., Cioffi, S. M. G., Oldoni, E., Riz, M. D. D., Basilico, P., et al. (2017) · Multiple Sclerosis · doi:10.1177/1352458516674566 · Cited by 38 · see citing works

Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes

Pietroboni, A. M., Carandini, T., Colombi, A., Mercurio, M., Ghezzi, L., Giulietti, G., Scarioni, M., Arighi, A., Fenoglio, C., Riz, M. A. D., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4182-1 · Cited by 39 · see citing works

CSF β-amyloid predicts prognosis in patients with multiple sclerosis

Pietroboni, A., Caprioli, M., Carandini, T., Scarioni, M., Ghezzi, L., Arighi, A., Cioffi, S. M. G., Cinnante, C., Fenoglio, C., Oldoni, E., et al. (2018) · Multiple Sclerosis · doi:10.1177/1352458518791709 · Cited by 29 · see citing works

Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers

Filippo, M. D., Gaetani, L., Salvadori, N., Chipi, E., Gentili, L., Borrelli, A., & Parnetti, L. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.286949 · Cited by 36 · see citing works

Role of amyloid-β CSF levels in cognitive deficit in MS

Gentile, A., Mori, F., Bernardini, S., & Centonze, D. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.035 · Cited by 32 · see citing works

Amyloid-β Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis

Bassi, M. S., Garofalo, S., Marfia, G. A., Gilio, L., Simonelli, I., Finardi, A., Furlan, R., Sancesario, G. M., Giandomenico, J. D., Storto, M., et al. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00390 · Cited by 29 · see citing works

Heteromers of amyloid precursor protein in cerebrospinal fluid

Cuchillo‐Ibáñez, I., López‐Font, I., Boix-Amorós, A., Brinkmalm, G., Blennow, K., Molinuevo, J. L., & Sáez‐Valero, J. (2015) · Molecular Neurodegeneration · doi:10.1186/1750-1326-10-2 · Cited by 27 · see citing works

Metabolomic Biomarkers of Multiple Sclerosis: A Systematic Review

Lachlan, P., Shoushtarizadeh, A., Jelinek, G. A., Brown, C. R., Lim, C. K., Livera, A. M. D., Jacobs, K. R., & Weiland, T. J. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.574133 · Cited by 25 · see citing works

APP‐derived peptides reflect neurodegeneration in frontotemporal dementia

Illán‐Gala, I., Pegueroles, J., Montal, V., Alcolea, D., Vilaplana, E., Bejanin, A., Borrego‐Écija, S., Sampedro, F., Subirana, A., Sánchez‐Saudinós, M., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50948 · Cited by 20 · see citing works

Unraveling the Connection of Epstein–Barr Virus and Its Glycoprotein M146–157 Peptide with Neurological Ailments

Patra, P., Rani, A., Sharma, N., Mukherjee, C., & Jha, H. C. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00231 · Cited by 15 · see citing works

Top-down peptidomics of bodily fluids

Martelli, C., Iavarone, F., Vincenzoni, F., Cabras, T., Manconi, B., Desiderio, C., Messana, I., & Castagnola, M. (2014) · Peptidomics · doi:10.2478/ped-2014-0005 · Cited by 13 · see citing works

CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers

Rostgaard, N., Roos, P., Portelius, E., Blennow, K., Zetterberg, H., Simonsen, A. H., & Nielsen, J. E. (2017) · Neurology · doi:10.1212/wnl.0000000000004799 · Cited by 13 · see citing works

Protein fibril aggregation on red blood cells: a potential biomarker to distinguish neurodegenerative diseases from healthy aging

Schneider, T. R., Stöckli, L., Felbecker, A., & Nirmalraj, P. N. (2024) · Brain Communications · doi:10.1093/braincomms/fcae180 · Cited by 10 · see citing works

Cerebrospinal fluid biomarkers of neurodegeneration in narcolepsy type 1

Baiardi, S., Pizza, F., Polischi, B., Moresco, M., Abu‐Rumeileh, S., Plazzi, G., & Parchi, P. (2019) · SLEEP · doi:10.1093/sleep/zsz215 · Cited by 11 · see citing works

Low CSF β-amyloid levels predict early regional grey matter atrophy in multiple sclerosis

Pietroboni, A. M., Colombi, A., Carandini, T., Contarino, V. E., Ghezzi, L., Fumagalli, G., Arighi, A., Fenoglio, C., Riz, M. A. D., Triulzi, F. M., et al. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101899 · Cited by 7 · see citing works

Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study

Johansson, K., Wasling, P., Novakova, L., Sjödin, S., Brinkmalm, A., Brinkmalm, G., Blennow, K., Zetterberg, H., & Axelsson, M. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103846 · Cited by 8 · see citing works

Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis

Padovani, A., Canale, A., Schiavon, L., Masciocchi, S., Imarisio, A., Risi, B., Bonzi, G., Giuli, V. D., Luca, M. D., Ashton, N. J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12554 · Cited by 7 · see citing works

CSF β-amyloid predicts early cerebellar atrophy and is associated with a poor prognosis in multiple sclerosis

Pietroboni, A. M., di Cola, F. S., Colombi, A., Carandini, T., Fenoglio, C., Ghezzi, L., Riz, M. A. D., Triulzi, F. M., Scarpini, E. A., Padovani, A., et al. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101462 · Cited by 7 · see citing works

Medical Histories of Control Subjects Influence the Biomarker Potential of Plasma Aβ in Alzheimer’s Disease: a Meta-analysis

Zhang, S., Huang, S., An, X., Zeng, L., & Ai, J. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01510-1 · Cited by 6 · see citing works

DNA intercalators as amyloid assembly modulators: mechanistic insights

Singh, J., Srivastava, A., Sharma, P. V., Pradhan, P. C., & Kundu, B. (2017) · RSC Advances · doi:10.1039/c6ra26313e · Cited by 5 · see citing works

CSF β-amyloid is not a prognostic marker in multiple sclerosis patients

Petitfour, J., Ayrignac, X., Ginestet, N., Prin, P., Dalliere, C. C., Hirtz, C., Charif, M., Lehmann, S., & Labauge, P. M. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104096 · Cited by 4 · see citing works

The Serum Amyloid β Level in Multiple Sclerosis: A Case- Control Study

Etemadifar, M., Ghadimi, M., Ghadimi, K., & Alsahebfosoul, F. (2017) · Caspian Journal of Neurological Sciences · doi:10.29252/nirp.cjns.3.11.214 · Cited by 13 · see citing works

Neuroglial biomarkers in autoimmune encephalitis: advances in diagnosis, prognosis, and pathophysiological insights

Borioni, M. S., Morano, A., Matteis, A. L. D., Mazzeo, A., Moro, P., Bonaventura, C. D., & Irelli, E. C. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08406-1 · Cited by 3 · see citing works

Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements

Nerattini, M., Rubino, F., Arnone, A., Polito, C., Mazzeo, S., Lombardi, G., Puccini, G., Nacmias, B., Cristofaro, M. T. D., Sorbi, S., et al. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05704-2 · Cited by 3 · see citing works

Molecular biomarkers and cognitive impairment in multiple sclerosis: A review

Esmaeili, S., Obeidat, A. Z., & Zabeti, A. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100077 · Cited by 3 · see citing works

Levels of 17β-Hydroxysteroid Dehydrogenase Type 10 in CSF are not a Valuable Biomarker For Multiple Sclerosis

Krištofiková, Z., Říčný, J., Kaping, D., Klaschka, J., Kotoucova, J., & Bartoš, A. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0061 · Cited by 3 · see citing works

Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

Mattsson, N., Grigoriou, S., & Zetterberg, H. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_11 · Cited by 2 · see citing works

On cerebrospinal fluid biomarkers of HIV-1 infection

Krut, J. J. (2015)

Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

Mattsson, N., & Zetterberg, H. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6380-0_9

Case report: Chorea and cognitive decline in a young woman: instrumental and genetic assessment of a case originally diagnosed as multiple sclerosis

Dato, C., Micaglio, E., Moresco, G., Rondinone, O., Vitali, P., Pappone, C., Fontana, L., Miozzo, M. R., & Bet, L. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1129289

Reduced serum AHR agonistic activity reflects amyloid dysregulation in AT1 subtypes of Alzheimer’s disease

Tsaktanis, T., Rudtke, L., Ammon, L., Mestermann, S., Rothhammer, V., Lewczuk, P., Maler, J. M., Kornhuber, J., & Oberstein, T. J. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01978-w

Cerebrospinal Fluid Levels of Soluble Amyloid Precursor Protein and β-Amyloid 42 in Patients with Multiple Sclerosis, Neuromyelitis Optica and Clinically Isolated Syndrome

Mai, W.-H., Hu, X.-Q., Lu, Z.-H., Peng, F.-H., & Wang, Y.-G. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900641 · Cited by 17 · see citing works

Investigation of the pathophysiology of progression in multiple sclerosis: studies on cerebrospinal fluid biomarkers

Axelsson, M. (2013) · Gothenburg University Publications Electronic Archive (Gothenburg University)

Identification of CSF Biomarkers of Cognitive Impairment and Cerebellar Dysfunction in Multiple Sclerosis (P03.230)

Bell, L., Harris, V., & Sadiq, S. A. (2013) · Neurology · doi:10.1212/wnl.80.7_supplement.p03.230 · Cited by 1 · see citing works

O4‐02‐08: Altered amyloid metabolism in neuroinflammation

Mattsson, N., Blennow, K., Zetterberg, H., & Hagberg, L. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.529

Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers

Ottervald, J., Franzén, B., Nilsson, K. C., Andersson, L. I., Khademi, M., Eriksson, B., Kjellström, S., Marko‐Varga, G., Végvári, Á., Harris, R. A., et al. (2010) · Journal of Proteomics · doi:10.1016/j.jprot.2010.01.004 · Cited by 141 · see citing works